UDCA with or without steroids in small-duct PSC with IgG4
Does UDCA alone provide a superior biochemical response compared to UDCA with low‑dose corticosteroids in patients with small‑duct PSC and IgG4 overlap
Out of scope for this tool. The focus of this literature tool is the surgical management of IBD. For medical management and drug dosing, please see ChatIBD.com.
The retrieved excerpts do not compare ursodeoxycholic acid alone versus ursodeoxycholic acid plus low-dose corticosteroids specifically in small-duct PSC with IgG4 overlap, so no such head-to-head biochemical-response claim can be made. The excerpts address other overlap settings only: in PSC-autoimmune-hepatitis and other overlap syndromes, treatment typically combines ursodeoxycholic acid with immunosuppression (corticosteroids or azathioprine), with variable and often incomplete responses 1–3.
References
- Fiske HW, Saeed F, Ward C, Sinayuk B, Ulici V, Curry M, Feller E, Shah SA. Coexisting Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Overlapping Challenges in Diagnosis and Treatment. Case Rep Gastroenterol. 2024. PMID: 38532799.
- Poupon R, Chazouillères O, Poupon RE. Chronic cholestatic diseases. J Hepatol. 2000. PMID: 10728800.
- Czaja AJ. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol. 2013. PMID: 23862175.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
⚠ Required context not in this corpus (severe). The high-dose UDCA (28-30 mg/kg/d) trial in PSC was TERMINATED at 6 years for futility, and reported HARM: a 2.3x higher risk of the primary endpoint, 2.1x higher death/transplantation/minimal listing criteria (P = 0.04), and serious adverse events in 63% vs 37% (Lindor 2009, PMID 19585548; Imam 2011, PMID 21957881).
Why this matters: An answer that calls high-dose UDCA merely 'unproven', or leaves open that a higher dose might help, can push a clinician toward a dose an RCT stopped for harm.
Added by the landmark interlock. This corpus is surgical in scope and cannot admit the source paper (PMID 19585548, 21957881). Not generated by the RAG.
⚠ Required context not in this corpus (moderate). High-dose UDCA is associated with the development of colorectal neoplasia in UC-PSC (Eaton 2011, PMID 21556038).
Why this matters: Omitting the neoplasia signal understates the risk of a drug still prescribed in this population.
Added by the landmark interlock. This corpus is surgical in scope and cannot admit the source paper (PMID 21556038). Not generated by the RAG.
Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.
Reviewer notes